Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wuxi Apptec Co. Ltd.
Industry Sector: HealthTechnology
CEO: Min Zhang Chen, PhD; Ge Li, PhD; Qing Yang
Number Of Employees: 39,414
Enterprise Value: $20,307,809,929
PE Ratio: 20.7
Exchange/Ticker 1: Shanghai:603259
Exchange/Ticker 2: HKEX:2359
Latest Market Cap: $25,890,027,258
BioCentury | Mar 18, 2025
Data Byte
Wuxi stocks bounce back as Biosecure threat fades
Shares of Wuxi Apptec and Wuxi Biologics are closing in on pre-Biosecure levels
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Dec 31, 2024
Deals
Drumbeat of China deals steady through year-end
Wuxi Apptec moves to preserve its core interests, GLP-1R deals showcase breadth of China biotech’s dealmaking
BioCentury | Dec 9, 2024
Politics, Policy & Law
Biosecure setback amid lawmakers’ push to reduce reliance on China
Defense bill places biotech under national security umbrella
BioCentury | Dec 5, 2024
Politics, Policy & Law
Biosecure compromise in the works, fate uncertain as deadline nears
Deal among lawmakers would give targeted companies chance to avoid sanctions
BioCentury | Nov 19, 2024
Politics, Policy & Law
As Congress considers Biosecure, report says WuXi companies low-risk
Rhodium Group report suggests Congress focus on economic rather than military threats from China biotech
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Oct 1, 2024
Product Development
Schizophrenia and sickle cell drugs, D.C. update: a BioCentury podcast
A first-in-class approval for BMS. A Pfizer withdrawal. ODAC & PD-L1. Congress’ unfinished business. BioAge’s NASDAQ IPO
BioCentury | Sep 27, 2024
Data Byte
CDMO shares rally on Biosecure’s slowing momentum, upbeat WuXi AppTec outlook
Stocks of China CDMOs, genomics companies rise as U.S. lawmakers head home with bill seeking to rein in select Chinese biotechs in limbo
BioCentury | Sep 24, 2024
Politics, Policy & Law
Pediatric PRVs, Biosecure & Novo’s obesity miss: a BioCentury podcast
Misunderstandings on priority review vouchers in Congress. A door closes for Biosecure. Setback for Novo Nordisk
Items per page:
1 - 10 of 220